HuGE Literature Finder
Records 1-7
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Cancer chemotherapy and pharmacology 2013 Nov 72 (5): 953-64. Park Sook Ryun, Hong Yong Sang, Lim Hyeong-Seok, Seong Moon-Woo, Kong Sun-Young, Kim Sun Young, Park Young-Iee, Jung Kyung H |
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
British journal of cancer 2013 Sep 109 (6): 1420-7. Kim S Y, S Hong Y, K Shim E, Kong S-Y, Shin A, Baek J Y, Jung K |
A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
Oncology 2012 82 (5): 5. Choi YH, Kim TW, Kim KP, Lee SS, Hong YS, Ryu MH, Lee JL, Chang HM, Ryoo BY, Kim HS, Shin JG, Kang YK |
A phase I/II study of combination therapy of S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 (15_suppl): e15023. Choi Y, Kim T, Lee S, Lee J, Chang H, Kim H, Shin J, Lee J, Kang |
A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer.
Pharmacogenetics and genomics 2005 Aug 15 (8): 535-46. Landi Stefano, Gemignani Federica, Moreno Victor, Gioia-Patricola Lydie, Chabrier Amélie, Guino Elisabeth, Navarro Matilde, de Oca Javier, Capellà Gabriel, Canzian Federico, |
A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer.
Carcinogenesis 2002 Nov 23 (11): 1839-49. Sachse Christoph, Smith Gillian, Wilkie Murray J V, Barrett Jennifer H, Waxman Robin, Sullivan Frank, Forman David, Bishop D Timothy, Wolf C Roland, |
[Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients].
Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 0 38 (4): 283-90. Cortejoso L, García M I, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández L |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 15, 2021
- Content source: